Survey on the Effect of Health Related Quality of Life (QOL) Associated With Compliance of Carbocisteine in Asthma Patients

Kyorin Pharmaceutical

Status: Completed

Conditions: Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT01693471

SEARCH-2012

Details and patient eligibility

About

The objectives of this study are to investigate the influence on HR-QOL (SF-36 v2) resulting from the compliance of MUCODYNE Tablets or MUCODYNE DS (Dry Syrup) 50% in asthma patients whose control levels are partly controlled or uncontrolled.

Full description

Period: 2012-2013 Observation Time: 0 week, 4 week

Matters investigated:

1. QOL determination using SF-36 v2
2. Medication compliance (VAS scale)
3. Gender, age, diagnosis, asthma subtype, severity, duration of disease, level of asthma control, concomitant drugs, comorbidities, smoking, alcohol, work

Enrollment: 179 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients ≥ 20 years of age
• Outpatients
• Patients with mild or moderate persistent asthma
• Patients with phlegm
• Patients whose levels of asthma control are partly controlled or uncontrolled
• Patients who are planned to treat MUCODYNE
• Patients who voluntarily submitted written consent forms upon participation in this study

Exclusion criteria

• Patients with a history of adverse reactions to carbocisteine
• Patients with serious cardiac, hepatic, renal, pulmonary, or hematological disease
• Patients with the possibility of pregnancy or suspected pregnancy
• Patients with complication of malignancy
• Current smoker
• Patients with definitive diagnosis for COPD
• Other patients whom investigators or subinvestigators considered inappropriate to participate in this study

Trial design

179 participants in 1 patient group

SEARCH Study Group